Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation

• Päätekijät: Yuhong Jiang (Tekijä), Xin Zhuo (Tekijä), Xiujuan Fu (Tekijä), Yue Wu (Tekijä), Canquan Mao (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Drug resistance can notably restrict clinical applications of gefitinib that is a commonly used EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for non-small cell lung cancer (NSCLC). The attempts in exploring novel drug targets and reversal strategies are still needed, since gefitinib resistance has no...